Brexpiprazole Impurity 42
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

Brexpiprazole Impurity 42

● In Stock

Catalogue No.:VE0025313
CAS No.:N/A
Mol. Formula:C25H27N3O3
Mol. Weight:417.50 g/mol

Additional information on Brexpiprazole Impurity 42

Parent drug

Brexpiprazole

IUPAC Name

7-(4-(4-(benzofuran-4-yl)piperazin-1-yl)butoxy)quinolin-2(1H)-one

Pharmacopoeial Synonyms

N/A

Other Synonyms

N/A

Smiles

O=C(C=C1)NC2=C1C=CC(OCCCCN(CC3)CCN3C4=CC=CC5=C4C=CO5)=C2

InChI

InChI=1S/C25H27N3O3/c29-25-9-7-19-6-8-20(18-22(19)26-25)30-16-2-1-11-27-12-14-28(15-13-27)23-4-3-5-24-21(23)10-17-31-24/h3-10, 17-18H, 1-2, 11-16H2, (H, 26, 29)

Description

Brexpiprazole Impurity 42 is a characterized process-related impurity detected in Brexpiprazole batches with low-level presence in the impurity profile. Analytical data indicate retention behavior consistent with a moderately polar degradation or synthetic byproduct | resolved by reversed-phase HPLC and confirmed by LC-MS and high-resolution mass spectrometry. Structural elucidation by NMR suggests substitution pattern variants of the parent scaffold | potentially affecting potency and safety margins if uncontrolled. Risk-based control strategies include validated chromatographic methods | specification limits | forced-degradation studies | and targeted purification steps to mitigate formation. Routine monitoring in stability and release testing ensures regulatory compliance and product quality assurance.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url